INFLUENZA IMMUNIZATION
Clinical trials for INFLUENZA IMMUNIZATION explained in plain language.
Never miss a new study
Get alerted when new INFLUENZA IMMUNIZATION trials appear
Sign up with your email to follow new studies for INFLUENZA IMMUNIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One shot for two viruses? combo COVID-Flu vaccine moves forward
⭐️ VACCINE ⭐️ CompletedThis study tested a single combination vaccine that aims to protect against both COVID-19 and influenza at the same time. About 980 adults aged 50 and older received either the combo shot, a flu shot alone, a COVID-19 shot alone, or both shots separately. Researchers monitored sa…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
One shot for two viruses? new combo vaccine trial shows promise
⭐️ VACCINE ⭐️ CompletedThis study tested a single combination vaccine that targets both COVID-19 and influenza in adults aged 50 and older. About 980 participants received either the combo shot, the flu vaccine alone, the COVID-19 vaccine alone, or separate shots in each arm. Researchers monitored safe…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New mRNA vaccine targets bird flu pandemic threat
⭐️ VACCINE ⭐️ CompletedThis study tested a new mRNA vaccine designed to protect against H5 pandemic flu strains. Researchers gave 276 healthy adults one of three doses or a placebo to check safety and immune response. The goal is to find the right dose for future studies.
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE1, PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New mRNA flu shot enters first human tests
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tested a new mRNA-based flu vaccine in 233 healthy adults aged 18 and older. The study compared three different doses of the experimental vaccine to a standard high-dose flu shot. Researchers monitored safety and immune responses over time to see if the new…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 17:10 UTC
-
New mRNA flu shot enters human testing
⭐️ VACCINE ⭐️ CompletedThis early-stage trial tests a new mRNA-based flu vaccine in 159 adults aged 18-49 and 60+. The vaccine uses modified mRNA to target a specific flu strain (H3N2). Researchers compare its safety and immune response to a standard flu shot. The goal is to gather data to improve futu…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 15:40 UTC
-
New flu vaccine shows promise for teens and adults
⭐️ VACCINE ⭐️ CompletedThis study tested a recombinant flu vaccine (RIV4) in over 1,300 people aged 9 to 49. The goal was to see if the immune response in children and teens (9-17) was as good as in adults (18-49). Researchers measured antibody levels before and 29 days after vaccination. The trial als…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 14:35 UTC
-
Super-Sized flu shot aims to better shield seniors
Prevention CompletedThis study tested a high-dose flu vaccine against a standard-dose one in 2,100 adults aged 60 and older in Japan. The goal was to see if the high-dose version triggers a stronger immune response. Participants received one shot and were followed for 28 days to measure antibody lev…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Supercharged flu vaccine shows promise for seniors
Prevention CompletedThis study tested whether a high-dose flu vaccine (QIV-HD) works better than the standard-dose vaccine in adults aged 60 and older. Over 1,500 healthy volunteers received either the high-dose or standard shot. Researchers measured immune responses 28 days later to see if the high…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 16:38 UTC
-
One-Stop shot? study combines flu and COVID boosters for seniors
Prevention CompletedThis study looked at whether it's safe and effective to give a high-dose flu vaccine and a Moderna COVID-19 booster at the same time to adults 65 and older. 306 volunteers who had already received two Moderna shots took part. Researchers measured side effects and antibody levels …
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE2 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated Jun 26, 2026 16:36 UTC
-
New flu vaccine tolerability survey completed with over 1,000 participants
Knowledge-focused CompletedThis study looked at how adults aged 18 and older experienced a trivalent recombinant influenza vaccine. Over 1,000 participants completed a short online survey about their injection experience, side effects, and willingness to get vaccinated again. The goal was to better underst…
Matched conditions: INFLUENZA IMMUNIZATION
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
German flu shot survey aims to boost vaccination rates
Knowledge-focused CompletedThis study surveyed 5,000 German adults to find out how many people got their flu shot during the current respiratory season. The focus was on adults aged 60 and older, as well as those with chronic illnesses. By collecting this data, researchers hope to help public health offici…
Matched conditions: INFLUENZA IMMUNIZATION
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Blood samples from kids and seniors could shape next Year's flu vaccine
Knowledge-focused CompletedThis study collected blood samples from 90 healthy children (6 months to under 9 years) and adults aged 65 and older who received the 2020-2021 flu vaccine. The samples were sent to experts at the WHO, CDC, and FDA to help decide which flu strains to include in future vaccines. T…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE4 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:33 UTC
-
Blood samples from flu shots could shape Tomorrow's vaccines
Knowledge-focused CompletedThis study collected blood samples from 90 healthy children (6 months to under 9 years) and adults 65 and older after they received their seasonal flu vaccines. The samples were sent to health authorities to help decide which flu strains to include in future vaccines. The study d…
Matched conditions: INFLUENZA IMMUNIZATION
Phase: PHASE4 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:27 UTC